Nvidia and TSMC to unveil first domestic wafer for Blackwell chips, Axios reports
Investing.com - Wolfe Research raised its price target on Johnson & Johnson (NYSE:JNJ) to $225.00 from $200.00 on Wednesday, while maintaining an Outperform rating on the stock.
The research firm cited Johnson & Johnson’s strong commercial execution for key products, including Carvykti, Tremfya, and Darzalex, as factors behind the increased price target. Wolfe Research also pointed to expected margin expansion in the latter half of the decade as supporting the higher valuation.
Johnson & Johnson has outperformed the market year-to-date with a 32% gain, compared to the DRG index’s 7% increase, despite facing headwinds from Stelara erosion. The company’s Innovative Medicine segment has shown re-acceleration, contributing to the stock’s strong performance.
The pharmaceutical sector has faced significant uncertainty in 2025, with Most Favored Nation pricing and ongoing talc litigation remaining focal points for Johnson & Johnson specifically, according to Wolfe Research.
Despite these macroeconomic challenges, Wolfe Research remains confident in Johnson & Johnson’s outlook, as reflected in its maintained Outperform rating and higher price target.
In other recent news, Johnson & Johnson reported its third-quarter earnings for 2025, surpassing analysts’ expectations. The company achieved an earnings per share (EPS) of $2.80, compared to the forecasted $2.76, and reported revenue of $23.99 billion, exceeding the anticipated $23.76 billion. Following these results, Stifel raised its price target for Johnson & Johnson to $190 from $165, while maintaining a Hold rating on the stock. This decision was influenced by the company’s better-than-expected earnings results and positive business outlook commentary. These developments highlight recent progress and adjustments in financial expectations for the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.